INMNasdaqPharmaceutical PreparationsFiscal year ends June 30

InMed Pharmaceuticals Inc.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 9, 2026

$1.37+0.05 (+3.44%)

Close on Oct 19, 2026

Market cap: $6.42M
P/E (TTM): –
Dividend yield: –

InMed Pharmaceuticals Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30
Revenue	–	4.94	4.60	4.14	1.09	1.90	–
Cost of Revenue	–	3.24	3.50	2.73	0.55	–	–
Gross Profit	–	1.71	1.10	1.40	0.54	–	–
Research & Development	3.03	2.82	3.22	3.73	7.28	5.34	5.81
General & Administrative	6.66	5.41	5.80	5.85	6.87	4.48	3.23
Operating Expenses	12	8.47	9.30	9.83	18	9.94	9.15
Operating Income	–	–	–	-7.95	-19	-10	–
Interest & Investment Income	0.24	0.16	0.53	0.49	0.10	0.02	0.13
Other Non-Operating Income	–	–	0.53	0.49	-1.34	-0.36	–
Asset Impairment Charges	0.19	–	–	–	2.02	–	–
Gain (Loss) on Sale of Assets	-0.01	–	–	–	-0.01	0.00	0.00
Pretax Income	-11	-8.69	-7.67	-7.93	-19	–	–
Income Tax Expense	–	–	0.01	0.01	–	–	–
Income from Continuing Operations	-11	-8.69	–	–	–	–	–
Income from Discontinued Operations	-1.19	0.53	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	7.90	19	10	8.90
Net Income	-13	-8.16	-7.68	-7.95	-19	-10	-8.94
Net Income to Common	-13	-8.16	–	–	–	–	–
EPS (Basic)(per share)	-3.12	-8.36	-20.14	-65.00	-663.40	-759.20	-855.00
EPS (Diluted)(per share)	-3.12	-8.36	-20.14	-65.00	-663.40	-759.20	-855.00
Shares Outstanding (Basic, Weighted)(shares)	4.16	0.98	0.38	0.12	0.03	0.01	0.01
Shares Outstanding (Diluted, Weighted)(shares)	4.16	0.98	0.38	0.12	0.03	0.01	0.01
EBITDA	–	–	–	-7.75	-18	-10	–
Net Interest Income	–	–	–	–	–	-0.36	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: -173.1%

Financial strength

Current ratio: 1.37
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 112.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 5.97
Dividend yield: –